INmune Bio Plunges 55.53% on Equity Offering, Clinical Trial Disappointment

On June 30, 2025, INmune Bio's stock experienced a significant drop of 55.53% in pre-market trading, marking a substantial decline in its share price.

INmune Bio's recent equity offering announcement has led to a notable decrease in its stock price. The company initiated a $19 million direct stock offering, which has raised concerns among investors about potential dilution and the company's financial strategy. This news has contributed to the volatility in INmune Bio's stock, leading to a trading halt due to the significant price fluctuations.

Additionally, INmune Bio's top-line results from a recent clinical trial have also impacted its stock performance. The company revealed the results, which did not meet investor expectations, further contributing to the decline in its share price. This news has added to the overall negative sentiment surrounding the company, leading to a significant drop in its stock value.